IMG_E1413

コメント

  • コメント (10)

  • トラックバックは利用できません。

  1. Diflucan is excreted in human milk, requiring careful risk-benefit analysis during lactation.

  2. Diflucan is used for secondary prophylaxis in HIV patients with prior fungal infections.

  3. Diflucan resistance can emerge during long-term suppressive therapy.

  4. Diflucan is a Schedule H/P drug in many countries, requiring a prescription.

  5. Development of resistance during long-term suppressive therapy is a documented risk.

  6. May significantly increase cyclosporine and tacrolimus levels, requiring close monitoring.

  7. First-line for uncomplicated vulvovaginal candidiasis due to high efficacy and patient convenience.

  8. Diflucan is available in both oral tablet/suspension and intravenous formulations.

  9. Diflucan exhibits fungistatic, not fungicidal, activity against most susceptible yeasts.

  10. Can cause taste distortion (dysgeusia) in some patients.